Drugs for Myelofibrosis/Polycythemia Vera
Find financial assistance programs available for myelofibrosis/polycythemia vera drugs.
Inrebic (fedratinib) Capsules
Drug company: Bristol Myers Squibb
Inrebic is a kinase inhibitor oral medication used for the treatment of adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis, a type of chronic blood cancer.
Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Inrebic:
BMS Oncology Co-Pay Assistance Program
This program provides financial assistance with out-of-pocket deductible, copay, or co-insurance costs for eligible patients with private insurance who have been prescribed Inrebic. Patients pay a $10 copay, and BMS covers the remaining amount, up to $15,000 annually.
Bristol Myers Squibb Patient Assistance Foundation
BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Inrebic may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.
Drug company: Incyte
Jakafi is a kinase inhibitor used for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. Jakafi is also used for patients with polycythemia vera who cannot use or cannot benefit from treatment with hydroxyurea. Myelofibrosis, polycythemia vera, and essential thrombocythemia are 3 types of myeloproliferative neoplasms (or MPNs), which are rare and chronic blood cancers and have only a few approved treatments.
Incyte offers 3 financial assistance programs for patients
who are using Jakafi:
IncyteCARES for Jakafi Savings Program
Patients with commercial or private insurance who are eligible to receive Jakafi pay as little as $0 monthly. The amount of savings will not exceed $11,977 monthly and $25,000 annually.
To enroll in this program, patients must call IncyteCARES (855-452-5234) to determine eligibility; a membership number is provided immediately and a copay/co-insurance card is activated for eligible patients. To receive copay assistance, patients must contact the specialty pharmacy and provide copay information. Eligible patients experiencing an insurance coverage delay can receive a free supply of Jakafi.
IncyteCARES Patient Assistance Program
Patients without prescription drug coverage for Jakafi, or
those whose insurance has denied claims, may be eligible
to receive the drug free of charge through this program. To
enroll in this program, patients must reside in the United
States or Puerto Rico, have an annual household income of
less than $125,000 or 600% of the federal poverty level,
whichever is greater, and have a valid prescription for an
Patients and their providers must complete the enrollment
form and fax it to 855-525-7207 or mail it directly to the
address listed on the form.
IncyteCARES Temporary Access Program
Eligible patients who experience a delay in insurance coverage
may be able to receive a free 30-day supply of Jakafi.
Patients must have private or commercial coverage to
qualify for this program.
Table. Drugs Prescribed for Myelofibrosis or Polycythemia Vera
- Drug name (generic name)
- Drug company
- Patient support services
Last modified: April 1, 2022